Compare Eli Lilly And Co (LLY) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

PALL (Aberdeen Physical Palladium Shares ETF) trades at $24.87, down 0.96% over 24 hours. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, though oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a buying opportunity. The ETF provides exposure to physical palladium, which has declined 47% from January 2026 highs.

The outlook for PALL hinges on palladium's supply-demand dynamics and industrial demand recovery. Investment opportunity exists if palladium prices rebound from current depressed levels, supported by supply risks and potential catch-up trade. Key risks include continued commodity price volatility, Federal Reserve policy uncertainty, and weaker industrial demand affecting palladium's fundamental drivers.